ATE414537T1 - Antikörper enthaltende stabilisierte zubereitungen - Google Patents
Antikörper enthaltende stabilisierte zubereitungenInfo
- Publication number
- ATE414537T1 ATE414537T1 AT02762901T AT02762901T ATE414537T1 AT E414537 T1 ATE414537 T1 AT E414537T1 AT 02762901 T AT02762901 T AT 02762901T AT 02762901 T AT02762901 T AT 02762901T AT E414537 T1 ATE414537 T1 AT E414537T1
- Authority
- AT
- Austria
- Prior art keywords
- preparations containing
- containing antibodies
- stabilized preparations
- stabilized
- acetyltryptophan
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 2
- DZTHIGRZJZPRDV-LBPRGKRZSA-N N-acetyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H](NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-LBPRGKRZSA-N 0.000 abstract 2
- 230000004071 biological effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001258988 | 2001-08-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE414537T1 true ATE414537T1 (de) | 2008-12-15 |
Family
ID=19086420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02762901T ATE414537T1 (de) | 2001-08-29 | 2002-08-29 | Antikörper enthaltende stabilisierte zubereitungen |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7682608B2 (de) |
| EP (1) | EP1428537B1 (de) |
| JP (1) | JP4342941B2 (de) |
| AT (1) | ATE414537T1 (de) |
| DE (1) | DE60229961D1 (de) |
| WO (1) | WO2003018056A1 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY150740A (en) * | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
| WO2005063291A1 (ja) * | 2003-12-25 | 2005-07-14 | Kirin Beer Kabushiki Kaisha | 抗体を含有する安定な水性医薬製剤 |
| WO2008068885A1 (ja) * | 2006-11-30 | 2008-06-12 | Sanyo Chemical Industries, Ltd. | 凍結乾燥用保護剤及び生理活性物質の製造方法 |
| TW200837080A (en) * | 2007-01-09 | 2008-09-16 | Wyeth Corp | Anti-IL-13 antibody formulations and uses thereof |
| AU2008250518B2 (en) * | 2007-05-16 | 2013-09-12 | Ktb Tumorforschungsgesellschaft Mbh | Low-viscous anthracycline formulation |
| JP4812807B2 (ja) * | 2007-06-27 | 2011-11-09 | 三洋化成工業株式会社 | タンパク質含有水溶液安定化剤及びタンパク質含有水溶液の安定化方法 |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| US20110086163A1 (en) * | 2009-10-13 | 2011-04-14 | Walbar Inc. | Method for producing a crack-free abradable coating with enhanced adhesion |
| JP5919606B2 (ja) | 2010-11-11 | 2016-05-18 | アッヴィ バイオテクノロジー リミテッド | 改良型高濃度抗ｔｎｆアルファ抗体液体製剤 |
| MY174679A (en) * | 2013-03-13 | 2020-05-06 | Genentech Inc | Formulations with reduced oxidation |
| US20140314778A1 (en) | 2013-03-13 | 2014-10-23 | Genentech, Inc. | Formulations with reduced oxidation |
| CN104977408B (zh) * | 2015-06-15 | 2016-09-14 | 暨南大学 | 一种筛选分泌特异性单克隆抗体杂交瘤细胞的方法与应用 |
| US20170239355A1 (en) * | 2015-12-30 | 2017-08-24 | Genentech, Inc. | Use of tryptophan derivatives for protein formulations |
| AR124914A1 (es) | 2021-02-18 | 2023-05-17 | Mitsubishi Tanabe Pharma Corp | Nuevo anticuerpo anti-pad4 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5157113A (en) | 1987-08-10 | 1992-10-20 | Miles Inc. | Removal of nucleic acids from monoclonal antibody preparations |
| EP0303088B1 (de) | 1987-08-10 | 1992-11-11 | Miles Inc. | Gereinigtes IgM |
| EP0465513A1 (de) | 1989-03-27 | 1992-01-15 | Centocor, Inc. | Formulierungen zur stabilisierung von igm-antikörpern |
| JPH0768137B2 (ja) | 1989-06-15 | 1995-07-26 | 株式会社ミドリ十字 | アルブミン製剤及びその製法 |
| TWI240627B (en) | 1996-04-26 | 2005-10-01 | Chugai Pharmaceutical Co Ltd | Erythropoietin solution preparation |
| EP0852951A1 (de) * | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| AUPO871997A0 (en) * | 1997-08-25 | 1997-09-18 | Csl Limited | Dried biologically or therapeutically active preparations |
| ATE512225T1 (de) * | 1998-04-03 | 2011-06-15 | Chugai Pharmaceutical Co Ltd | Humanisierter antikörper gegen den menschlichen gewebefaktor (tf) und verfahren für die konstruktion eines solchen humanisierten antikörpers. |
| EP1260230A4 (de) * | 2000-02-29 | 2008-08-06 | Chugai Pharmaceutical Co Ltd | Langfristig stabilisierte präparate |
-
2002
- 2002-08-29 EP EP02762901A patent/EP1428537B1/de not_active Expired - Lifetime
- 2002-08-29 WO PCT/JP2002/008732 patent/WO2003018056A1/ja not_active Ceased
- 2002-08-29 JP JP2003522572A patent/JP4342941B2/ja not_active Expired - Fee Related
- 2002-08-29 US US10/488,050 patent/US7682608B2/en not_active Expired - Fee Related
- 2002-08-29 AT AT02762901T patent/ATE414537T1/de not_active IP Right Cessation
- 2002-08-29 DE DE60229961T patent/DE60229961D1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US7682608B2 (en) | 2010-03-23 |
| JP4342941B2 (ja) | 2009-10-14 |
| WO2003018056A1 (fr) | 2003-03-06 |
| JPWO2003018056A1 (ja) | 2004-12-09 |
| EP1428537A1 (de) | 2004-06-16 |
| EP1428537A4 (de) | 2005-11-09 |
| EP1428537B1 (de) | 2008-11-19 |
| DE60229961D1 (de) | 2009-01-02 |
| US20040213785A1 (en) | 2004-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60229961D1 (de) | Antikörper enthaltende stabilisierte zubereitungen | |
| DK2316852T3 (da) | Stabiliserede enkeltdomæne-antistoffer | |
| EP1674480A4 (de) | Antikörper, der den die tgf-beta-aktivierung steuernden regionsabschnitt erkennt | |
| WO2004041865A3 (en) | Stabilized single domain antibodies | |
| NO2017028I2 (no) | eftrenonacog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet. | |
| DE60329489D1 (de) | Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon | |
| DE69638269D1 (de) | Hochaffine humane antikörper gegen tumorantigene | |
| CY1114164T1 (el) | Μεθοδος ελεγχου της δραστικοτητας ανοσολογικα λειτουργικου μοριου | |
| DK1454138T3 (da) | Immunocytokiner med moduleret selektivitet | |
| ATE485835T1 (de) | Antikörper enthaltende pharmazeutische lösungen | |
| EP1698640A4 (de) | Verfahren zur stabilisierung von antikörpern und stabilisierte antikörperzubereitung vom lösungstyp | |
| ATE316982T1 (de) | Mehrere zytokin-antikörper komplexen | |
| EE200300408A (et) | Aktiivsete valkude saagise suurendamine | |
| DK1025227T3 (da) | Humane TOLL-homologer | |
| DE50209000D1 (de) | PH-Wert-geregeltes Polyamidpulver | |
| DE60332711D1 (de) | Neue insektizide proteine von bazillus thuringiensis | |
| ITBO20010545A0 (it) | Articolo per la coltivazione di specie orticole | |
| EA200600042A1 (ru) | Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах | |
| DE60322727D1 (de) | Rückgefaltetes Membranprotein in monodisperser Form | |
| EA200000016A1 (ru) | Гидроксициклопентанон | |
| WO2003057821A3 (en) | Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses | |
| AU2002245255A1 (en) | Regulation of target protein activity through modified proteins | |
| DE69817915D1 (de) | Harnstoff- und Thioharnstoffderivate von antibiotisch wirksamen Glykopeptiden | |
| ATE186567T1 (de) | Verwendung von azolen als virustötende substanzen in lösungen von biologisch aktiven proteinen | |
| BR0210575A (pt) | Compostos de 2-(fenila 2,6-dissubstituìda)-4-aril-5-alquil-1,3-oxazolina úteis como inseticidas e acaricidas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |